Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted ...

Myriad Genetics and Lumea Inc. partner to integrate ... This integration aims to enhance the efficiency of ordering and delivering molecular tests, allowing healthcare providers to electronically ...

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, today announced the launch of IONA® Care+, a fully comprehensive non-invasive prenatal ...

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and ...

MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Anti-Microbial/Anti-Fungal Tests MarketThe global anti-microbial/anti-fungal tests market is poised for significant growth, ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and ...

Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader ...